Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [5463]

$European Commission grants marketing authorization for lenvatinib in advanced RAI-refractory differentiated thyroid cancer$

European Commission grants marketing authorization for lenvatinib in advanced RAI-refractory differentiated...

ASCO 2015: Obinutuzumab doubles remission duration in patients with relapsed, indolent non-hodgkin lymphoma

ASCO 2015: Obinutuzumab doubles remission duration in patients with relapsed, indolent non-hodgkin lymphoma

ASCO 2015: New ibrutinib combination regimen shows substantial benefits in relapsed chronic lymphocytic leukaemia

ASCO 2015: New ibrutinib combination regimen shows substantial benefits in relapsed chronic lymphocytic leukaemia

ASCO 2015: Pembrolizumab shows promising activity against head and neck cancer

ASCO 2015: Pembrolizumab shows promising activity against head and neck cancer

Deadly ovarian cancer outsmarts chemotherapy

Deadly ovarian cancer outsmarts chemotherapy

ASCO 2015: Adding elotuzumab significantly reduces risk of progression for relapsed multiple myeloma

ASCO 2015: Adding elotuzumab significantly reduces risk of progression for relapsed multiple myeloma

Mortality and incidence for most breast cancer subtypes continue to decline

Mortality and incidence for most breast cancer subtypes continue to decline

Trial of new ‘resistance-busting’ skin cancer drug begins as first patient receives treatment

Trial of new ‘resistance-busting’ skin cancer drug begins as first patient receives treatment

Multiple types of resistance to new lung cancer drug identified

Multiple types of resistance to new lung cancer drug identified

Study points to possible treatment for lethal paediatric brain cancer

Study points to possible treatment for lethal paediatric brain cancer

More from ecancer